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Abstract
Objective: The aim of this study was to identify the treatment gaps that pertain to risk factors in South African 
patients with type 2 diabetes mellitus, using national treatment guidelines.
Design: Cross-sectional study.
Setting and subjects: The study consisted of 666 patients with type 2 diabetes mellitus, attending a diabetes clinic 
at the Charlotte Maxeke Johannesburg Academic Hospital.
Outcome measures: Using a public sector database, retrospective data were obtained on the treatment of type 
2 diabetes mellitus participants. Patients were randomly selected on the basis of established type 2 diabetes 
mellitus diagnosis, and if they were receiving oral hypoglycaemic and/or insulin therapy. Age, gender, race, blood 
pressure, haemoglobin A1c (HbA1c) and fasting lipids were captured and measured. The history of patients’ previous 
coronary artery disease, strokes, nephropathy, neuropathy and retinopathy was recorded.  
Results: The mean age of the patients was 63 years [standard deviation (SD) 11.9], 55% of whom were females. 
The HbA1c was 8.8% (SD 2.5). 26.2% of patients attained HbA1c levels of < 7%. Of the total patients, 45.8% met a 
< 130/80 mmHg blood pressure target, and 53.8% a low-density lipoprotein (LDL) cholesterol of < 2.5 mmol/l. Only 
7.5% obtained the combined target for HbA1c , blood pressure and LDL cholesterol.
Conclusion: Traditionally, type 2 diabetes mellitus treatment has centred on correcting blood glucose levels. Yet, 
as many as 80% of people with type 2 diabetes mellitus die from some form of cardiovascular disease (CVD). Many 
trials have demonstrated the benefits of targeting CVD risk factors (HbA1c, blood pressure and lipids) in patients with 
type 2 diabetes mellitus. Despite the wealth of evidence, our data suggest that significant undertreatment of risk 
factors in patients with type 2 diabetes mellitus remains. 
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Introduction
Diabetes mellitus is a serious, multifaceted condition. 
The aetiological types of diabetes are type 1, type 2, 
gestational diabetes and other specific types.1 Insulin-
dependent type 1 diabetes mellitus may present in 
childhood, and is associated with pancreatic β-cell 
destruction, but it is outweighed by the more common 
type 2 diabetes mellitus.2 Type 2 diabetes mellitus 
has emerged as one of the most common chronic 
conditions throughout the world. The incidence of type 
2 diabetes mellitus is approximately 10 times higher 
than that of type 1 diabetes.3 In 2010, it was estimated 
that approximately 285-million people globally were 
diabetic, and that by 2030, an estimated 439-million 
people will be living with diabetes worldwide.4
Treatment in patients with either form of diabetes has 
centred around the correction of blood glucose levels. 
Insulin is used to reduce hyperglycaemia in patients with 
type 1 diabetes, while a more varied and multifaceted 
armamentarium is available for glycaemic control 
in those with type 2 diabetes mellitus. Yet, as many 
as 80% of patients with type 2 diabetes mellitus die 
from some form of cardiovascular disease (CVD).5 This 
highlights the need for a more intense intervention 
to reduce cardiovascular risk factors. A number of 
interventions and other epidemiological surveys have 
demonstrated that blood pressure targets are far lower 
in this risk group.6 Serum lipid targets are also set at 
lower levels than those for non-diabetics. As the risk of 
cardiovascular disease increases by at least three- to 
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fourfold, this necessitates more intensive therapy for 
cardiovascular risk factors in this patient population.
The 2009 guidelines issued by the Society for 
Endocrinology, Metabolism, and Diabetes of South 
Africa (SEMDSA), and in use at the time of this study, 
suggested aggressive targeting of haemoglobin A1c 
(HbA1c), but also of blood pressure and dyslipidaemia.
7 
The question remains: how well are treatment 
guidelines translated into clinical practice? And how 
many patients are meeting targets, and if not, how far 
are they away from doing so?
We wished to document the extent to which patients 
with type 2 diabetes mellitus were being managed 
in a South African, public sector setting. The cohort 
comprised patients who were initially referred from their 
primary local clinics to a tertiary public sector clinic. This 
reflects the quality of care that the state can provide, 




This was a cross-sectional study designed to evaluate 
the extent to which the 2009 SEMDSA treatment 
guidelines were followed in a tertiary-based type 2 
diabetic population. The study period coincided with 
the publication of these guidelines. Therefore, it was 
appropriate to assess the data against these. This was 
achieved by comparing blood pressure, serum glucose 
and lipid levels in treated patients with type 2 diabetes 
against the national treatment targets. 
Setting
The study was conducted at the Charlotte Maxeke 
Johannesburg Academic Hospital between July 2008 
and 2009. This academic tertiary hospital provides 
healthcare services to patients across Gauteng 
province. Generally, enrolled patients in this clinic 
are not covered by the private healthcare industry. 
In addition, patients in these clinics are only enrolled 
once their treating physicians at the primary clinics 
have referred them. Management is carried out at 
the diabetic clinic and patients attend the clinic for 
purposes of follow-up and maintenance.
Patients
We extracted data from a sample of 666 patients 
attending the hospital’s diabetic clinic. At the time of 
the study, the latest diagnosing type 2 diabetes mellitus 
criteria issued by SEMDSA were applied to the cohort.7 
Patients were excluded from the study if they were 
< 18 years of age, had type 1 diabetes, gestational 
diabetes, steroid-induced diabetes and chronic 
pancreatitis which had led to secondary diabetes. As 
one of the primary measurements was a serum lipid 
reading, a decision was taken to exclude patients with 
triglyceride levels > 5.0 mmol/l as this may have been a 
source of error when calculating low-density lipoprotein 
(LDL) cholesterol, as measured by the Friedewald 
formula,8 or could have been noncompliance with 
overnight fasting, leading to anomalous lipid readings, 
and in particular, falsely low LDL cholesterol readings. 
The study participants were enrolled in a consecutive 
sequential manner, based on their assigned computer-
generated hospital numbers and the first letter of their 
surnames. 
Using patient records, clinical data were captured 
into case report forms, including demographics (age, 
gender and ethnicity), systolic blood pressure (SBP), 
diastolic blood pressure (DBP), glycated HbA1c, total 
cholesterol, LDL cholesterol, high-density lipoprotein 
(HDL) cholesterol, triglycerides (TGs), a family history, 
cardiovascular history and chronic medication. 
Unfortunately, most patient files had incomplete details 
of weight, height, diet details and smoking status. 
These parameters, especially the first two, would have 
been used to calculate body mass index. Also, patient 
classification with regard to metabolic syndrome was 
also omitted from the study owing to absent waist 
measurements.9 Incomplete details of ethnicity in the 
patient files were denoted as “unknown.” 
Patients defined as having diabetic nephropathy using 
laboratory data, i.e. microalbumin to creatinine ratios, 
serum creatinine concentrations or glomerular filtration 
rate, often proved inconsistent because many patients 
did not have the available laboratory reports in their 
records. It was also found that some patients were 
concurrently managed at the hospital’s renal clinic, 
separate to the diabetic clinic. For the purposes of this 
study, patients deemed to have diabetic nephropathy 
were those with one or more of the following in 
their records: chronic kidney disease, chronic renal 
disease, chronic renal failure (CRF), nephropathy and 
diabetic nephropathy. Only the most recent records 
and laboratory reports of patients were utilised for 
the purposes of this study. Data from the CRF were 
entered into a secure database at the Faculty of 
Health Sciences, University of the Witwatersrand, 
Johannesburg. Prior to the study, the University of the 
Witwatersrand’s Human Research Ethics Committee 
granted ethical approval of the study (ethics protocol 
number M080409). 
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Clinical parameters
Where blood samples were required for laboratory 
tests, registered nurses were in charge of drawing the 
study patients’ blood, using standardised techniques 
at the diabetes clinic. Patients were informed of the 
mandatory fasting requirements that pertained to the 
tests before having their blood drawn for specific tests 
in prior appointments or visits. 
As Charlotte Maxeke Johannesburg Academic Hospital 
is a state hospital, the National Health Laboratory 
Services (NHLS) was responsible for the study patients’ 
laboratory measurements. Once the results were 
available, the NHLS issued laboratory results delivered 
by hospital staff to the diabetes clinic, and filed under 
respective patient files by clinic administration staff. 
HbA1c was measured using the Tina-quant Hemoglobin 
A1c II immunological assay, fasting LDL cholesterol 
was calculated by means of the Friedewald formula, 
fasting HDL cholesterol was measured by direct 
enzymatic methods (third generation), fasting total 
cholesterol was also calculated by direct enzymatic 
methods, and TGs were measured by enzymatic 
colorimetric methods. Measurements were carried 
out using the Modular Analyser P800 System® (Roche 
Diagnostics, Mannheim, Germany). Blood pressure 
readings were measured by registered nurses or 
treating doctors, using standardised brachial cuff 
techniques in accordance with the latest (at the time 
of the study) South African hypertension guidelines and 
The seventh report of the Joint National Committee on 
the prevention, detection, evaluation and treatment 
of high blood pressure (JNC 7).10,11 Once data 
were captured into case reports, the SEMDSA 
2009 guidelines for type 2 diabetes mellitus 
treatment targets were applied to the cohort, 
namely SBP < 130 mmHg and DBP < 80 mmHg. 
HbA1c < 7%, total cholesterol < 4.5 mmol/l, LDL 
cholesterol < 2.5 mmol/l, HDL cholesterol > 1 
mmol/l (men), HDL cholesterol > 1.2 mmol/l 
(women) and TGs < 1.7 mmol/l. The LDL 
cholesterol target was ≤ 1.8 mmol/l in patients 
with established vascular disease, such as 
ischaemic heart disease, cerebrovascular 
disease or peripheral vascular disease. 
Hypertension was present if patients were 
receiving antihypertensive treatment.
Statistical and data analysis
Simple statistics were calculated for age, 
gender, race, blood pressure, HbA1c and 
fasting lipids. The percentage of previous 
coronary artery disease (CAD), strokes, 
nephropathy, neuropathy and retinopathy 
history in patients was reported. Patient usage 
of chronic medication to treat hyperglycaemia, 
hypertension and lipids, as well as receiving anti-
platelet treatment was analysed. The percentage 
of patients reaching the SEMDSA treatment goals for 
various clinical parameters was also calculated. A 
significance level of 5% was used for the analysis. Where 
necessary, ratios were compared using the chi-square 
test. Unpaired Student’s t-tests were used to compare 
mean differences. Microsoft Office® Excel® 2009 was 
utilised for the study’s databases and statistical analysis 
was carried out using Statistica® version 8.
Results
The cohort consisted of 666 patients, of whom 369 
(55%) were women. Ages ranged from 29-94 years. The 
mean age for men was 62 [standard deviation (SD) 
12.0] vs. 63 (SD 11.8) years for the women (p-value 0.56) 
(Table I). The patient ethnicity of the cohort was 42.8% 
African, 29.4% Caucasian, 19.5% Asian, 5.9% mixed 
ancestory and 2.4% unknown (using patient records 
with incomplete data).
The mean SBP readings for the cohort were 134 mmHg 
(SD 20.0) and 79 mmHg for DBP (SD 11.7). Of the cohort, 
85.4% were hypertensive. More women than men were 
being treated for hypertension (88.4% vs. 81.9%, p-value 
< 0.05). Most of the patients were receiving angiotensin-
converting enzyme inhibitors (80.0%). Diuretics were 
prescribed to 69.8%. Approximately 46.6% were taking 
calcium-channel blockers, and 17.6% β blockers.
DBP targets (< 80 mmHg) were achieved more easily 
than those for SBP (69.1% vs. 54.6%, p-value <0.01) 








Age (years) 63 ± 11.9 62 ± 12.0 63 ± 11.8 0.56
SBP (mmHg) 134 ± 20.0 132 ± 20.6 136 ± 19.4 < 0.05
DBP (mmHg) 79 ± 11.7 78 ± 13.2 79 ± 10.3 0.58
HbA1c (%) 8.8 ± 2.5 8.5 ± 2.3 8.9 ± 2.6 0.05
Total cholesterol (mmol/l) 4.6 ± 1.2 4.5 ± 1.2 4.8 ± 1.1 < 0.05
Triglycerides (mmol/l) 1.8 ± 1.0 1.8 ± 1.0 1.7 ± 1.0 0.41
HDL cholesterol (mmol/l) 1.2 ± 0.4 1.1 ± 0.4 1.3 ± 0.4 < 0.05
LDL cholesterol (mmol/l) 2.6 ± 0.9 2.5 ± 0.9 2.7 ± 0.9 0.98
Hypertension, n (%) 569 (85.4) 243 (81.8) 326 (88.3) < 0.05
CAD, n (%) 95 (14.3) 44 (14.8) 51 (13.8) < 0.05
Stroke, n (%) 20 (3.0) 9 (3.0) 11 (3.0) 0.34
Nephropathy, n  (%) 78 (11.7) 41 (13.8) 37 (10.0) 0.54
Neuropathy, n  (%) 47 (7.1) 25 (8.4) 22 (6.0) 0.75
Retinopathy, n  (%) 42 (6.3) 26 (8.8) 16 (4.3) 0.38
*: p-value for sex differences, significant if p-value < 0.05
CAD: coronary artery disease, DBP: diastolic blood pressure, HbA1c: haemoglobin A1c, HDL: high-density 
lipoprotein, LDL: low-density lipoprotein, SBP: systolic blood pressure
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in patients with no apparent signs of diabetic 
nephropathy. Only 45.8% reached the goals for both 
SBP and DBP. In other words, over 54% did not achieve 
the target. 
In this cohort, 11.1% had documented nephropathy. 
More rigorous blood pressure targets are set by 
SEMDSA for these patients (SBP ≤ 120 mmHg and DBP 
≤ 70 mmHg). Control rates were poor. 25.5% of these 
patients achieved the SBP goal, and 32.7% the DBP 
goal. Only 16.4% met the combined SBP and DBP 
target.
The mean HbA1c for the cohort was 8.8% (SD 2.5). 
Patients on insulin monotherapy had the highest 
HbA1c 9.4% (SD 2.6). HbA1c for patients on insulin and 
hypoglycaemic combination therapy was 9.1% 
(SD 2.3). The lowest HbA1c of 6.3% (SD 1.0) was present in 
patients on diet alone. In the cohort, just over a quarter 
(26.2%) of patients reached the SEMDSA treatment 
target of HbA1c < 7 %.
The TCs for the population were 4.6 mmol/l (SD 1.2), 
with a calculated LDL cholesterol of 2.6 mmol/l (SD 0.9). 
TGs were measured at 1.8 mmol/l (SD 1.0), and HDL at 
1.3 mmol/l (SD 0.4) for women and 1.1 mmol/l (SD 0.4) 
for men. The total cholesterol target of < 4.5 mmol/l was 
obtained by 53.8% of patients. 60.2% reached the TG 
target of < 1.7 mmol/l.
Previously established CAD or strokes were present in 
103 of the 666 patients. Of these, 81.9% failed to reach 
LDL cholesterol (≤ 1.8 mmol/l). 53.8% of patients with a 
lower risk profile (no previous CAD or strokes) reached 
the SEMDSA LDL cholesterol goal of < 2.5 mmol/l. 
The majority of statin users (59.1%) were prescribed 
simvastatin 20 mg.
Of the patients with no history of heart disease, 40.7% 
received antiplatelet therapy. In the group with a 
history of CAD only, just over half (56 of the 103 patients) 
were on antiplatelet therapy.
Discussion
In South Africa, the human immunodeficiency virus/
acquired immune deficiency syndrome epidemic 
has mushroomed over the last two decades and has 
consumed scarce resources in the public sector.12As 
the South African population becomes urbanised 
and more affluent, diseases of lifestyle, such as type 
2 diabetes mellitus, have proliferated. Mortality rates 
in South Africa have revealed a 41% increase due to 
non-communicable diseases, with CVD and type 2 
diabetes mellitus growing alarmingly.13 
This study aimed to investigate the management 
of a cohort of South African patients with type 2 
diabetes mellitus based on the SEMDSA 2009 treatment 
guidelines prevailing at the time of the study. These 
guidelines advocate strict control of glucose, but also 
control of blood pressure and lipids. Results from this 
study indicate that the attainment of treatment goals 
remains suboptimal. Less than half of the total cohort 
met their goal pertaining to the blood pressure target, 
although over 85% were receiving antihypertensive 
medication. Even more alarmingly, the SEMDSA HbA1c 
target of < 7 % was achieved by just over one quarter of 
the population, even though almost the entire cohort 
was receiving glucose-lowering therapy. More patients 
met the LDL cholesterol, than the blood pressure or 
glycaemic control for serum lipids, goal (Figure 1). 
Given that small, dense and atherogenic particles of 
LDL cholesterol predominate in type 2 diabetes mellitus, 
these levels may underestimate the actual risk.14
Overall, less than 10% of the study population achieved 
the treatment goals for all three risk factors (serum 
glucose, blood pressure and cholesterol). Comparable 
findings have been seen in other observational studies. 
In an Italian study, in which 2 465 patients were 
recruited, only 5% achieved the recommended goals 
for LDL cholesterol, blood pressure, glycated HA1c and 
smoking habits.15 Similarly, a Czech study concluded 
that 1% of their patients achieved similar goals, while 
6% of the total cohort that consisted of 975 patients in a 
Norwegian study met the goal for the combined target 
of glucose, blood pressure and cholesterol control.16,17 
It is clear that the gap between type 2 diabetes 
mellitus treatment and goals is not necessarily confined 
to developing countries, but also affects countries with 
greater available resources.







LDL < 2.5 mmol/l
45.8%
 BP < 130/80 mmHg
Figure 1: Percentage of study type 2 diabetics at goal using the 
Society for Endocrinology, Metabolism, and Diabetes of South 
Africa 2009 targets for glycaemia, blood pressure and lipids
BP: blood pressure, HbA1c: haemoglobin A1c, LDL: low-density lipoprotein 
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at a time when the previously issued guidelines were in 
place. This study may have overestimated the current 
number of patients who did not achieve the goal as 
the previously set targets were stricter in comparison to 
the newer and more individualised targets.18
In South Africa, resource scarcities in the public sector 
are a constant reality. Declining numbers of available 
clinicians lead to shortened consultation times. 
Patient education may be compromised for patients 
who do not speak the same first language as their 
treating practitioners.19 It is vital for patients with type 
2 diabetes mellitus to be fully aware of their risk factors 
and to know how to manage these effectively.20 
Further efforts in resource allocations and practitioner-
patient communication are undoubtedly necessary in 
addressing disease management issues.
In conclusion, the study evaluated adherence to 
recommended type 2 diabetes mellitus treatment 
guidelines and actual targets achieved by patients 
being managed in a resource-limited public sector 
setting. The results indicate disappointing achievement 
of national type 2 diabetes mellitus treatment targets. 
The goal of closing the gap between targets and what 
is realised remains elusive, given diminishing resources 
and limited physician-patient interaction.
Most patients with type 2 diabetes mellitus did not 
meet their targets for blood pressure, lipids and 
glycaemic control, in spite of receiving the necessary 
pharmacotherapy. The chasm between the target 
goals and actually reaching them is massive, and 
unlikely to narrow. Improvement lies in the form of 
therapeutic titration adjustment and patient education. 
Clearly, more aggressive therapeutic efforts, affected 
earlier, are needed to reduce overall microvascular 
and macrovascular outcomes.
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